Man Group
EDIT icon

Man Group’s Editas Medicine EDIT Stock Holding History

Man Group’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-125,511
Closed -$310K – 2410
2026
Q1 		$310K Buy
125,511
+46,341
+59% +$98.1K ﹤0.01% 2205
2025
Q4 		$162K Buy
79,170
+29,326
+59% +$84.7K ﹤0.01% 2156
2025
Q3 		$173K Buy
+49,844
New +$139K ﹤0.01% 2121
2024
Q4 		– Sell
-52,733
Closed -$180K – 2037
2024
Q3 		$180K Sell
52,733
-2,289
-4% -$9.96K ﹤0.01% 1871
2024
Q2 		$257K Sell
55,022
-46,745
-46% -$264K ﹤0.01% 1822
2024
Q1 		$755K Buy
101,767
+25,131
+33% +$209K ﹤0.01% 1643
2023
Q4 		$776K Buy
+76,636
New +$673K ﹤0.01% 1530
2023
Q3 		– Sell
-740,174
Closed -$6.35M – 871
2023
Q2 		$6.09M Buy
+740,174
New +$6.45M 0.02% 795
2023
Q1 		– Sell
-409,380
Closed -$3.64M – 903
2022
Q4 		$3.63M Buy
409,380
+99,727
+32% +$1.09M 0.01% 949
2022
Q3 		$3.79M Buy
+309,653
New +$4.82M 0.02% 834
2022
Q2 		– Hold
0
– – – 1893
2021
Q3 		– Sell
-14,041
Closed -$796K – 1944
2021
Q2 		$796K Buy
14,041
+6,603
+89% +$244K ﹤0.01% 1437
2021
Q1 		$313K Buy
+7,438
New +$424K ﹤0.01% 1617
2020
Q4 		– Sell
-20,610
Closed -$578K – 1843
2020
Q3 		$578K Sell
20,610
-34,935
-63% -$1.14M ﹤0.01% 1520
2020
Q2 		$1.64M Sell
55,545
-15,598
-22% -$408K 0.01% 1125
2020
Q1 		$1.41M Buy
71,143
+43,143
+154% +$1.09M 0.01% 1008
2019
Q4 		$829K Buy
28,000
+2,600
+10% +$64.9K ﹤0.01% 1524
2019
Q3 		$578K Sell
25,400
-38,720
-60% -$959K ﹤0.01% 1544
2019
Q2 		$1.59M Sell
64,120
-6,200
-9% -$148K 0.01% 1379
2019
Q1 		$1.72M Buy
+70,320
New +$1.59M 0.01% 1397
2018
Q3 		– Sell
-8,779
Closed -$315K – 2110
2018
Q2 		$315K Sell
8,779
-97,294
-92% -$3.44M ﹤0.01% 1915
2018
Q1 		$3.52M Buy
+106,073
New +$3.78M 0.02% 1039

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Man Group's EDIT Position: Q2 2026 in Review

Man Group sold out of Editas Medicine (EDIT) in Q2 2026, closing a stake of 125,511 shares — an estimated $310K sold.

Man Group first reported a position in EDIT in Q1 2018 and held it in 21 quarters. The position peaked at $6.09M in Q2 2023. 214 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Man Group reported no remaining Editas Medicine position as of Q2 2026 after selling out during the quarter.
  • Man Group sold 125,511 Editas Medicine shares in Q2 2026, an estimated $310K.
  • Man Group first reported a position in Editas Medicine in Q1 2018 and held it in 21 quarters.
  • Man Group's Editas Medicine position peaked at $6.09M in Q2 2023.
  • 214 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.